Home

END2AMR

Accelerating novel therapies to tackle antimicrobial resistance and chronic bacterial infections

Latest project updates

END2AMR (European Novel Drug Research to Address Microbial Infections and Drug Resistance) is a European research and innovation project tackling antimicrobial resistance (AMR), with a focus on drug-resistant bacterial infections that pose a major threat to public health. The project brings together academic, clinical, public health and industry partners to accelerate the discovery and development of new antibacterial solutions.

Partners
12

International partners in consortium

€ 30 million

Budget

Duration
5 years

Project duration, started on January, 2026

About END2AMR

Antimicrobial resistance (AMR) is one of the most serious global health threats of our time. Chronic and drug-resistant bacterial infections already cause millions of deaths worldwide each year and place an increasing burden on healthcare systems, economies, and societies. In Europe alone, tens of thousands of people die annually from resistant infections, and hospital-acquired infections continue to rise.

Despite the urgent need, innovation in antibacterial drug development has stalled. Most antibiotics in clinical use today are based on discoveries made decades ago, and only a handful of truly new classes have reached patients in the past 30 years. Scientific, economic, and regulatory challenges have led many pharmaceutical companies to withdraw from this area, leaving a fragmented innovation landscape.

END2AMR was created to address this gap by bringing together leading academic researchers, SMEs, industry, and non-profit organisations to develop novel therapeutic approaches that go beyond conventional antibiotics and can be translated into future patient treatments.

Follow us on LinkedIn

Lygature in END2AMR

As Project Coordinator, Lygature leads the project’s governance, project management, stakeholder engagement, data governance, and ethical oversight. Lygature will facilitate consortium-wide communication, support regulatory and health-policy interactions, and help ensure that END2AMR’s scientific outputs are positioned for downstream development and long-term impact. 

Lygature together with 

GSK (SP); University of Dundee (UK); Obulytix (BE); University of Copenhagen (DK); CEA (FR); Quadram Institute (UK); Francis Crick Institute (UK); University of Manchester (UK); Affilogic (FR); University of Liverpool (UK); TB Alliance (US); Stichting Lygature (NL).

Acknowledgement of support

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101253465. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, and Vaccines Europe. 

Project updates

  • END2AMR launches to accelerate innovation against drug-resistant bacterial infections

    Lygature is proud to announce the launch of END2AMR – a new public-private research initiative designed to tackle some of the most difficult-to-treat bacterial infections. Read more

Share this page…